Venus Remedies partners with UK-based Infex Therapeutics to develop anti-bacterial MET-X in India
Bringing a First-in-Class MBL Inhibitor to India: Venus Remedies Licenses MET-X
Venus Remedies has taken a significant step in combating Antimicrobial Resistance (AMR) by securing exclusive licensing rights for MET-X, an innovative anti-bacterial drug from UK-based Infex Therapeutics. This landmark partnership will enable Venus Remedies to develop, gain regulatory approvals, and commercialize MET-X in India, reinforcing its commitment to tackling drug-resistant infections.
MET-X is a first-in-class metallo-beta-lactamase (MBL) inhibitor designed to restore the effectiveness of Meropenem, a widely used antibiotic, against highly resistant Gram-negative bacteria. These pathogens pose a major global health threat, causing life-threatening infections that are becoming increasingly difficult to treat due to resistance to existing antibiotics.
By inhibiting metallo-beta-lactamases, MET-X effectively neutralizes bacterial resistance mechanisms, allowing Meropenem to function as a powerful treatment once again. This makes MET-X a crucial breakthrough in addressing some of the most pressing challenges in infectious disease treatment.
Under this agreement, Venus Remedies will lead the development, regulatory approvals, and commercialization of MET-X in India. The company plans to initiate a Phase I clinical trial in healthy volunteers, paving the way for its introduction in the Indian healthcare market. With its deep expertise in critical care, AMR-focused research, and Meropenem manufacturing, Venus Remedies is uniquely positioned to bring MET-X to patients in need.
AMR is recognized as one of the biggest global health threats, leading to increased mortality, prolonged hospital stays, and higher healthcare costs. India is among the countries heavily impacted by drug-resistant infections, making the development of innovative solutions like MET-X essential.
With the rise of carbapenem-resistant bacteria, particularly those producing metallo-beta-lactamases, the availability of MET-X could significantly improve patient outcomes and reduce dependency on last-resort antibiotics.
This partnership aligns with Venus Remedies' mission to pioneer groundbreaking medical solutions and reinforces its leadership in the field of AMR-focused drug development. The company has consistently invested in research and development, bringing high-impact, life-saving medicines to the forefront of healthcare.
The licensing of MET-X marks a strategic advancement for Venus Remedies in the Indian pharmaceutical landscape. By integrating cutting-edge innovations in antibiotic resistance management, the company aims to enhance treatment protocols and improve patient care.
With this development, Venus Remedies continues to expand its footprint in the global fight against AMR, ensuring that critical care medications remain effective and accessible.
The exclusive licensing of MET-X from Infex Therapeutics is a monumental achievement for Venus Remedies, strengthening its commitment to AMR research and positioning it at the forefront of pharmaceutical innovation in India. As the company moves forward with the clinical development and commercialization of MET-X, it reaffirms its mission to combat drug-resistant infections and safeguard global health.
